KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 112 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q4 2020. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $787,956 | +23.4% | 45,363 | +0.0% | 0.02% | +41.7% |
Q2 2023 | $638,683 | +34.4% | 45,361 | +2.7% | 0.01% | +33.3% |
Q1 2023 | $475,087 | -26.5% | 44,153 | +2.3% | 0.01% | -30.8% |
Q4 2022 | $646,417 | +16.7% | 43,152 | +0.0% | 0.01% | +18.2% |
Q3 2022 | $554,000 | +43.2% | 43,141 | +8.3% | 0.01% | +57.1% |
Q2 2022 | $387,000 | +4.9% | 39,832 | +7.6% | 0.01% | +16.7% |
Q1 2022 | $369,000 | -12.1% | 37,015 | +3.9% | 0.01% | +20.0% |
Q4 2021 | $420,000 | +2.7% | 35,614 | -0.6% | 0.01% | 0.0% |
Q3 2021 | $409,000 | +96.6% | 35,814 | +141.8% | 0.01% | +150.0% |
Q2 2021 | $208,000 | -24.4% | 14,812 | 0.0% | 0.00% | -33.3% |
Q1 2021 | $275,000 | +3.8% | 14,812 | -0.7% | 0.00% | 0.0% |
Q4 2020 | $265,000 | -72.8% | 14,912 | -76.5% | 0.00% | -75.0% |
Q3 2020 | $974,000 | -56.4% | 63,512 | -27.5% | 0.01% | -53.8% |
Q2 2020 | $2,233,000 | – | 87,607 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |